MYLOTARG (gemtuzumab ozogamicin)
ANTINEOPLASTIC MONOCLONAL ANTIBODIES·CD33 POSITIVE ACUTE MYELOID LEUKEMIA
Wyeth Pharmaceutical
Indication
CD33 positive acute myeloid leukemia
CD33-positive acute myeloid leukemia is an aggressive hematologic malignancy characterized by the clonal proliferation and accumulation of immature myeloid precursors (blasts) in the bone marrow and peripheral blood, defined by the surface expression of the CD33 transmembrane glycoprotein. Read more about CD33 positive acute myeloid leukemia
1 drugs 1 manufacturers
Drugs that treat it
Common CD33 positive acute myeloid leukemia therapies.
Filter & compare in the drug finder →Opens the drug finder with CD33 positive acute myeloid leukemia preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonCD33-positive acute myeloid leukemia is an aggressive hematologic malignancy characterized by the clonal proliferation and accumulation of immature myeloid precursors (blasts) in the bone marrow and peripheral blood, defined by the surface expression of the CD33 transmembrane glycoprotein.
This subtype affects both adult and pediatric populations and encompasses the majority of acute myeloid leukemia cases.
Pathophysiologically, the rapid expansion of leukemic blasts disrupts normal hematopoiesis, leading to bone marrow failure that clinically manifests as severe anemia, neutropenic infections, and thrombocytopenic bleeding.
The presence of the CD33 differentiation antigen serves as an essential immunophenotypic marker and a therapeutic target for myeloid-directed pharmacotherapies.
- nih.gov
CD33-positive acute myeloid leukemia is an aggressive hematologic malignancy characterized by the clonal proliferation and accumulation of immature myeloid precursors (blasts) in the bone marrow and peripheral blood, defined by the surface expression of the CD33 transmembrane glycoprotein Pathophysiologically, the rapid expansion of leukemic blasts disrupts normal hematopoiesis, leading to bone marrow failure that clinically manifests as severe anemia, neutropenic infections, and thrombocytopeni...
- nih.gov
CD33-positive acute myeloid leukemia is an aggressive hematologic malignancy characterized by the clonal proliferation and accumulation of immature myeloid precursors (blasts) in the bone marrow and peripheral blood, defined by the surface expression of the CD33 transmembrane glycoprotein This subtype affects both adult and pediatric populations and encompasses the majority of acute myeloid leukemia cases The presence of the CD33 differentiation antigen serves as an essential immunophenotypic ma...
- nih.gov
CD33-positive acute myeloid leukemia is an aggressive hematologic malignancy characterized by the clonal proliferation and accumulation of immature myeloid precursors (blasts) in the bone marrow and peripheral blood, defined by the surface expression of the CD33 transmembrane glycoprotein This subtype affects both adult and pediatric populations and encompasses the majority of acute myeloid leukemia cases The presence of the CD33 differentiation antigen serves as an essential immunophenotypic ma...
- msdmanuals.com
CD33-positive acute myeloid leukemia is an aggressive hematologic malignancy characterized by the clonal proliferation and accumulation of immature myeloid precursors (blasts) in the bone marrow and peripheral blood, defined by the surface expression of the CD33 transmembrane glycoprotein The presence of the CD33 differentiation antigen serves as an essential immunophenotypic marker and a therapeutic target for myeloid-directed pharmacotherapies
- mypathologyreport.ca
Pathophysiologically, the rapid expansion of leukemic blasts disrupts normal hematopoiesis, leading to bone marrow failure that clinically manifests as severe anemia, neutropenic infections, and thrombocytopenic bleeding
- haematologica.org
The presence of the CD33 differentiation antigen serves as an essential immunophenotypic marker and a therapeutic target for myeloid-directed pharmacotherapies
Personalize your experience
Follow CD33 positive acute myeloid leukemia and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.